Citations

Clear

355 citation(s) found for "Sherman, ME".

Cancer Incidence and Survival after Emergency Department Care in the U.S. Midwest: An Opportunity for Cancer Interception
Sherman, Mark E. , Heckman, Michael G. , DeStephano, Christopher C. , White, Launia J. , Pfeiffer, Ruth M. , St Sauver, Jennifer L , Pfeiffer, Ruth M , Heckman, Michael G , DeStephano, C C , Sherman, Mark E , Sauver, Jennifer L. St.

Mayo Clinic

Cancer Prevention Research | April 7, 2025 | Volume: 18 | Issue: 7 | Pages: 413-421

10.1158/1940-6207.capr-24-0426 | PMID 40192659 Get It

Abstract Historically, cancers diagnosed via the emergency department (ED) portend a poor prognosis. Recent data from the United States are sparse, and analyses of cancers detected in the years following ED visits are lacking. Thus, we analyzed data from nine rural U.S. Midwest counties included within the population-based Rochester Epidemiology Project (2015–2021). Participants without a history of cancer (N = 42,074) who did not receive ED care were matched 1:1 to ED participants on the date of ED visit, age, sex, race, ethnicity, and county of residence. Analyses were restricted to participants with records ≤2 years prior to ED or index visit and ≥30 days after. HRs and 95% confidence intervals (CI) comparing cancer incidence and deaths among ED and non-ED participants were estimated from Cox proportional hazards regression models, either unadjusted or adjusted for covariates. Cumulative cancer incidence curves accounting for competing risks of death and survival (all cause and cancer-specific) were estimated. The median follow-up was 6.3 years, with 2,719 (6.46%) cancers diagnosed among ED participants and 3,139 (7.46%) among non-ED participants. ED participants experienced lower cancer risk overall (HRAdjusted = 0.70; 95% CI, 0.66–0.74; P = 8.89 × 10−31), specifically for breast cancer, prostate cancer, melanoma, and secondary cancers. Cancer-specific mortality was higher among ED participants (HRAdjusted = 1.76; 95% CI, 1.49–2.08; P = 3.62 × 10−11). Compared with non-ED participants, ED participants experienced a lower incidence of cancer but higher overall cancer-specific mortality, suggesting that subsets of ED patients may benefit from postvisit preventive interventions. Prevention Relevance: This cohort analysis shows that cancer incidence over 6 years was lower among participants after an ED visit than among matched non-ED participants, whereas cancer-specific mortality was higher in the ED group (HRAdjusted = 1.76; 95% CI, 1.49–2.08; P = 3.62 × 10−11), suggesting the potential benefit of preventive interventions.
Response to Letter to the Editor From Zhang et al: “Cabozantinib Plus Ipilimumab/Nivolumab in Patients with Previously Treated Advanced Differentiated Thyroid Cancer”
Konda, Bhavana , Sherman, Eric J. , Ryder, Mabel , Agulnik, Mark , Handley, Demond , Moses, Catherine, Jacob, Rajani, Streicher, Howard , Shah, Manisha H. , Streicher, Howard , Ryder, Mabel , Massarelli, Erminia , Nieva, Jorgé , Muzaffar, Jameel, Morris, John C, Ho, Alan L. , Wei, Lai , Moses, Catherine, Jacob, Rajani, Wright, John, Carson, William E.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | April 4, 2025 | Volume: 110 | Issue: 7 | Pages: e2425-e2426

10.1210/clinem/dgaf221 | PMID 40184489 Get It

325 Advancing breast cancer risk identification and care in non-Hispanic Black Women
Cabezas, Jennifer Vanessa, Touré, Savanna, Ogony, Joshua, Sherman, Mark A., Stallings‐Mann, Melody , Pacheco-Spann, Laura M. , Sherman, Mark, Austin, Jessica D. , Radisky, Derek C.

Mayo Clinic

Journal of Clinical and Translational Science | March 25, 2025 | Volume: 9 | Issue: s1 | Pages: 100-100

10.1017/cts.2024.956 Get It

Objectives/Goals: This project will enrich our understanding of basal breast carcinogenesis, highlighting the distinct biological differences in breast cancer risk between non-Hispanic Black (NHB) or non-Hispanic White (NHW) women, but also has the potential to provide real-world solutions thereby contributing to reducing health disparities in breast cancer outcomes Methods/Study Population: In the biological investigation, I am utilizing a unique cohort of normal breast tissues from Mayo Clinic patients who underwent breast reduction surgery that have self-identified as NHB or NHW premenopausal women. From these tissues, we are able to subculture human mammary epithelial cells, which we will use for our consequent experiments. For the qualitative study, I aim to recruit up to 40–50 eligible NHB women identified at increased risk for breast cancer and conduct semi-structured qualitative interviews informed by the National Institute on Minority Health and Health Disparities Research Framework. Results/Anticipated Results: Gene expression profiling on our cohort of 15 NHB and 40 NHW premenopausal women identified a gene expression signature in NHB women indicative of elevated Hedgehog signaling, a key factor in triple-negative breast cancer (TNBC) development and progression. I hypothesize that persistent activation of Hedgehog signaling within NHB women instigates the proliferation and transformation of basal stem cells within the breast, thus fueling TNBC development. Understanding the perceptions and experiences of NHB women that are identified as being at an increased risk for BC will aid in the identification of barriers and facilitators to their risk reduction care and in turn provide implementation strategies that could contribute to alleviating the racial disparity seen in TNBC morbidity, mortality, and preventative care. Discussion/Significance of Impact: The significance of this project lies in its dual approach, uncovering basal breast cancer mechanisms in a high-risk group using normal breast tissue and evaluating the perspectives from NHB women to enhance the practical relevance of our findings.
Low-Dose Valacyclovir in Herpes Zoster Ophthalmicus
Cohen, Elisabeth J. , Liu, Mengling , Baratz, Keith H. , Mian, Shahzad I., Choulakian, Mazen Y., Warner, David B., Lu, Ying , Twi-Yeboah, Alberta , Kim, Jiyu , Lopez-Jimenez, Carlos, Laury, Sarah, Jeng, Bennie H., Weissbart, Sarah B. , Abazari, Azin, Chou, Timothy , Chang, Eileen , Amescua, Guillermo , Koo, Ellen, Galor, Anat , Berestka, John S., Nanji, Afshan, Stutzman, Richard D., Clements, John, Davies, Emma , Saeed, Hajirah N. , Ciralsky, Jessica, Fernández, A. Gómez-Bastero , Sippel, Kimberly C. , Perez-Quinones, Victor L, Daluvoy, Melissa B. , Liu, Katy C., Ewald, M., Groos, Erich B, Chang, Bernard, Shivitz, Ira A., Hill, Jordan , Fowler, Priscilla G., Read, Russell W. , Geggel, Harry S. , Rony, Sayegh, Rapuano, Christopher J. , Meghpara, Beeran, Holland, Gary N. , Irvine, John, Aldave, Anthony J. , Edmund, Tsui, Chen, Judy , Honig, Marc A, Snyder, Lee A, Lubniewski, Anthony J., Katz, Douglas, Capoor, Seema, Gonzales, John, Keenan, Jeremy, Morkin, Melina I., Kenyon, Kenneth R., Lee, William B., Christenbury, Joseph, LaMattina, Kara C. , Negahban, Kambiz, Rao, Ronihi, Ament, Christine S, Lopatynsky, Marta O., Barbato, John D, Sarkar, Jayati S, Macsai, Marian S., Herz, Joshua B, Al-Mohtaseb, Zaina , Matoba, Alice Y., Cooney, Theresa, Sugar, Alan , Shtein, Roni M., Nehls, Sarah, Warner, Evan J. , Nettune, Greg, Bowman, Brad, Gelender, Henry, Alexander, Jamie K. , McCall, Tyrone, Zaffos, Joshua, Beebe, Walter E., Potts, Luke B. , Lustbader, Jay M., Oboh-Weilke, Aruoriwo, Hammersmith, K.M., Orlin, Stephen E., Nagra, Parveen K., Sulewski, Michael E., Bunya, Vatinee Y. , Shafer, Brian M. , Viriya, Elizabeth T., Qureshi, Anam, Lazzaro, Douglas R., Palazzolo, Laura , Goyal, Himani , Schrack, Katie E, Raber, Irving M. , Ayres, Brandon D. , Finklea, Brenton, Reeves, Sherman W., Awad, Omar E, Hardten, David R., Reilly, Charles, Flynn, William J., Rashid, Edward D, Wen, Angie E, Harris, David J. , Shaik, Neha, Seedor, John A., Rosenfeld, Steven I., Winnick, Marc , Amir, Ahmad Fitri , Sherman, Mark D., Chaon, Benjamin, Soukiasian, Sarkis H., Rao, Naveen K. , Steiner, Anne, Winokur, Jules , Udell, Ira J., Shih, Carolyn, Gorski, Matthew , Schrier, Amilia, Lobo-Chan, Ann-Marie , Sugar, Joel, Munir, Wuqaas W, Sunshine, Sarah B. , Miller, Donald M. , Gensheimer, William G. , Zegans, Michael E. , Weiss, Jayne S. , Bernal, María José , Barron, Bruce J., Hindman, Holly B. , Wise, R., Gelston, Christopher D. , Taravella, Michael J. , Davidson, Richard S. , Tran, Uyen, Bartley, Jeremy, McCulley, James P., Verity, Steven M., Bowman, Wayne, Blomquist, Preston H. , Mootha, V. Vinod , Thorne, George, Renucci, Ann M, Verdier, David D. , Sivaraman, K. R., Nordlund, Michael L., Hwang, Frank S. , Affeldt, John E., Ingraham, Herbert J., Guibord, Nathalie M., Dobbins, Kendall, Thareja, Tarika , Zaugg, Brian , Mifflin, Mark D., FORSTOT, S. LANCE, Fish, Robert A, Repine, Karen, Wildes, Michael, Estopinal, Christopher B., Brown, Donna, Koreishi, Aaleya, Ple-plakon, Patricia, Clemons, Carol S., Ashe, S, Bonaffini, Sarah G. , Houser, Kourtney, Wallace, M. Christopher , Wesberry, Jesse M, Yeung, Sonia N. , Noordeh, Nima, Faucher, Anne, Robert, Marie‐Claude , Rullo, Jacob, Johnson, Davin , Mah, Dean, Chew, Hall F., Hassonlou, Mojgan, Liu, Shaohui , Eikenberry, Jennifer , Yung, Chi-Wah, Shen, Joanne F , Yu, Charles, Ta, Christopher N. , Goins, Kenneth M., Sutphin, John E., Svanda, Kerri, Keppol, Stacy, Rostov, Audrey Talley, Vyas, Neil , Hsu, Kimberly , Goodman, Gerri, McHam, Lisa, Oates, Dale, Rizkalla, Ramy, Shukla, Anita N. , Veena, Mathew , See, Craig W. , Feder, Robert S., Baqai, Jeanine, Basti, Surendra, Haddadin, Ramez I., You, Jae Young , Dixit, Lena, Patel, Ravi H, Golde, Kimberly T, Zaidman, Gerald W., Mahesh, Sankara, Wesolosky, Jason D., Jeffrey, Helen, Mannis, Mark J., Meyer, Jay J. , Niederer, Rachael L. , Colby, Kathryn , McLeod, Stephen D. , Melia, Michele , Sugar, Elizabeth A. , Taylor, Carol R., Nagel, Maria A. , Lass, Jonathan H. , Lu, Ying , Jeng, Bennie H. , Troxel, Andrea B. , Hochman, Judith S. , Mian, Shahzad I. , Warner, David B., Lu, Ying, Lee, Ting‐Fang , Tonk, Rahul Singh , Martinez, Jaime D. , Patel, Sanjay V. , Chamberlain, Winston , Chodosh, James , Fernandez, Ana G Alzaga, Hill, Jordan, Omar, Ahmed F. , Syed, Zeba A. , Lee, Olivia, Irvine, John, Deng, Sophie X. , Huang, Andrew , Margolis, Todd P. , Seitzman, Gerami D. , Hamrah, Pedram , Lee, Hyunjoo, Weikert, Mitchell P. , Hood, Christopher T. , Woodward, Maria A. , Shtein, Roni Mintz , Zaffos, Joshua, Prescott, Christina R. , Haberman, Ilyse D. , Ritterband, David C. , Harris, David J, Ahmad, Sumayya , Amir, Ahmad, Srikumaran, Divya S. , Akpek, Esen K. , Tu, Elmer Yuchen , Miller, Donald M, Bernal, Maria, Barron, Bruce, Wise, Ronald, Shieh, Christine , Thorne, George, Renucci, A., Sivaraman, Kavitha, Affeldt, John, Guibord, Nathalie M, Lin, Amy , Patel, Ravi, Asbell, Penny A. , Wallace, Michael, Iovieno, Alfonso , Teichman, Joshua C. , Robert, Marie-Claude , Harissi‐Dagher, Mona , Baxter, Stephanie A. , Benson, Matthew, Tone, Stephan Ong , Yung, C.–W., Lin, Charles C. , Vyas, Neil M, Oates, Dale, Veena, Mathew, Goshe, Jeffrey M. , Sharma, Vikas , Miller, Darby D. , Ma, Jeffrey H, Dupps, William Joseph

Mayo Clinic

JAMA Ophthalmology | March 6, 2025 | Volume: 143 | Issue: 4 | Pages: 269

10.1001/jamaophthalmol.2024.6114 | PMID 40048183 Get It

Importance High-quality evidence regarding suppressive valacyclovir treatment in herpes zoster ophthalmicus (HZO) is necessary to guide care. Objective To determine whether suppressive valacyclovir compared with placebo delays the occurrence of new or worsening stromal keratitis (SK), endothelial keratitis (EK), iritis, or dendriform epithelial keratitis (DEK) during 12 months of treatment and if treatment benefit persisted at 18 months (secondary end point). Design, Setting, and Participants The Zoster Eye Disease Study (ZEDS) was a randomized clinical trial conducted in 95 sites from November 2017 to June 2024. Immunocompetent, nonpregnant adults with a history of an HZO rash, documented active keratitis or iritis within 1 year, and an estimated glomerular filtration rate of 45 mL/min/1.73 m 2 or greater were eligible. After determined to be eligible, participants were randomized in 4 strata: age at onset (<60 years vs ≥60 years) and disease duration (<6 months vs ≥6 months). Interventions A total of 12 months of double-masked daily valacyclovir, 1000 mg, or placebo. Main Outcomes and Measures The primary outcome was time to first occurrence within 12 months of new or worsening SK, EK, iritis, or DEK. Results A total of 527 participants (median [IQR] age, 60 [50-68] years; 266 female [50.5%]; 266 in the valacyclovir group; 261 in the placebo group) were randomized in 4 strata; 481 completed 12 months, and 460 completed 18 months. Data were analyzed by intention to treat. At 12 months, primary end points occurred in 86 participants (33%) assigned to placebo and 74 (28%) assigned to valacyclovir, and at 18 months in 104 participants (40%) assigned to placebo and 86 (32%) assigned to valacyclovir. The hazard ratio (HR) of the primary end point at 12 months was 0.77 for participants taking valacyclovir vs placebo (HR, 0.77; adjusted 95% CI, 0.56-1.05; P = .09) and 0.73 at the secondary end point at 18 months (HR, 0.73; adjusted 95% CI, 0.55-0.97; P = .03). There was a reduction of multiple other secondary end points at 12 months (HR, 0.70; 95% CI, 0.52-0.95; P = .02) and 18 months (HR, 0.72; 95% CI, 0.55-0.95; P = .02). Conclusions and Relevance Although the primary outcome did not show a benefit of suppressive valacyclovir treatment, secondary study outcomes showed treatment superiority at the 18-month end point and reduced number of multiple episodes of keratitis or iritis at both 12 and 18 months. These results support consideration of 1 year of suppressive valacyclovir treatment for HZO. Trial Registration ClinicalTrials.gov Identifier: NCT03134196
Low-Dose Valacyclovir for Postherpetic Neuralgia in the Zoster Eye Disease Study
Warner, David, Jeng, Bennie H., Kim, Jiyu , Liu, Mengling , Baratz, Keith H. , Mian, Shahzad I., Choulakian, Mazen Y., Meyer, Jay J. , Lu, Ying , Twi-Yeboah, Alberta , Lopez-Jimenez, Carlos, Laury, Sarah, Cohen, Elisabeth J. , Weissbart, Sarah B. , Abazari, Azin, Chou, Timothy , Chang, Eileen , Amescua, Guillermo , Koo, Ellen, Galor, Anat , Berestka, John S., Nanji, Afshan, Stutzman, Richard D., Clements, John, Davies, Emma , Saeed, Hajirah N. , Ciralsky, Jessica, Fernández, A. Gómez-Bastero , Sippel, Kimberly C. , Perez-Quinones, Victor L, Daluvoy, Melissa B. , Liu, Katy C., Ewald, M., Groos, Erich B, Chang, Bernard, Shivitz, Ira A., Hill, Jordan , Fowler, Priscilla G., Read, Russell W. , Geggel, Harry S. , Rony, Sayegh, Rapuano, Christopher J. , Meghpara, Beeran, Holland, Gary N. , Irvine, John, Aldave, Anthony J. , Edmund, Tsui, Chen, Judy , Honig, Marc A, Snyder, Lee A, Lubniewski, Anthony J., Katz, Douglas, Capoor, Seema, Gonzales, John, Morkin, Melina I., Kenyon, Kenneth R., Lee, William B., Christenbury, Joseph, LaMattina, Kara C. , Negahban, Kambiz, Rao, Ronihi, Ament, Christine S, Lopatynsky, Marta O., Barbato, John D, Sarkar, Jayati S, Macsai, Marian S., Herz, Joshua B, Al-Mohtaseb, Zaina , Matoba, Alice Y., Cooney, Theresa, Hood, Christopher , Sugar, Alan M., Shtein, Roni M., Nehls, Sarah, Warner, Evan J. , Nettune, Greg, Bowman, Brad, Gelender, Henry, Alexander, Jamie K. , McCall, Tyrone, Zaffos, Joshua, Beebe, Walter E., Potts, Luke B. , Lustbader, Jay M., Oboh-Weilke, Aruoriwo, Hammersmith, K.M., Orlin, Stephen E., Nagra, Parveen K., Sulewski, Michael E., Bunya, Vatinee Y. , Shafer, Brian M. , Viriya, Elizabeth T., Qureshi, Anam, Lazzaro, Douglas R., Palazzolo, Laura , Goyal, Himani , Schrack, Katie E, Raber, Irving M. , Ayres, Brandon D. , Finklea, Brenton, Reeves, Sherman W., Awad, Omar E, Hardten, David R., Reilly, Charles, Flynn, William J., Rashid, Edward D, Wen, Angie E, Shaik, Neha, Seedor, John A., Rosenfeld, Steven I., Winnick, Marc , Amir, Ahmad, Sherman, Mark D., Chaon, Benjamin, Soukiasian, Sarkis H., Rao, Naveen K. , Steiner, Anne, Winokur, Jules , Udell, Ira J., Shih, Carolyn, Gorski, Matthew , Schrier, Amilia, Lobo-Chan, Ann-Marie , Sugar, Joel, Munir, Wuqaas W, Sunshine, Sarah B. , Miller, Donald M. , Gensheimer, William G. , Zegans, Michael E. , Weiss, Jayne S. , Bernal, M.L. , Barron, Bruce, Hindman, Holly B. , Wise, Ronald E. , Gelston, Christopher D. , Taravella, Michael J. , Davidson, Richard S. , Tran, Uyen, Bartley, Jeremy, McCulley, James P., Verity, Steven M., Bowman, Wayne, Blomquist, Preston H. , Mootha, V. Vinod , Thorne, George, Renucci, A., Verdier, David D. , Sivaraman, K. R., Nordlund, Michael L., Hwang, Frank S. , Affeldt, John, Ingraham, Herbert J., Guibord, Nathalie M, Dobbins, Kendall, Thareja, Tarika , Zaugg, Brian , Mifflin, Mark D., Forstot, S. Lance, Fish, Robert A, Repine, Karen, Wildes, Michael, Estopinal, Christopher B., Brown, Donna, Koreishi, Aaleya, Ple-plakon, Patricia, Clemons, Carol S., Patel, Ravi , Ashe, Sanda, Bonaffini, Sarah G. , Houser, Kourtney, Wallace, Michael A., Wesberry, Jesse M, Yeung, Sonia N. , Noordeh, Nima, Faucher, Anne, Rullo, Jacob, Johnson, Davin , Mah, Dean, Benson, Matthew , Chew, Hall F., Hassonlou, Mojgan, Liu, Shaohui , Eikenberry, Jennifer , Yung, Chi-Wah, Shen, Joanne F , Lin, Charles C. , Yu, Charles, Ta, Christopher N. , Goins, Kenneth M., Sutphin, John E., Svanda, Kerri, Keppol, Stacy, Rostov, Audrey Talley, Vyas, Neil , Hsu, Kimberly, Goodman, Gerri, McHam, Lisa, Oates, Dale, Rizkalla, Ramy, Shukla, Anita N. , Veena, Mathew , See, Craig W. , Feder, Robert S., Baqai, Jeanine, Basti, Surendra, Haddadin, Ramez I., You, Jae Young , Dixit, Lena, Patel, Ravi H, Golde, Kimberly T, Zaidman, Gerald W., Mahesh, Sankara, Sharma, Vikas, Wesolosky, Jason D., Jeffrey, Helen, Mannis, Mark J., Niederer, Rachael L. , Lu, Ying , Jeng, Bennie H. , Troxel, Andrea B. , Hochman, Judith S. , Mian, Shahzad I. , Lee, Ting‐Fang , Tonk, Rahul Singh , Martinez, Jaime D. , Patel, Sanjay V. , Chamberlain, Winston , Chodosh, James , Fernandez, Ana G Alzaga, Perez-Quinones, Victor L, Hill, Jordan, Omar, Ahmed F. , Syed, Zeba A. , Lee, Olivia, Irvine, John, Deng, Sophie X. , Edmund, Tsui, Huang, Andrew , Margolis, Todd P. , Seitzman, Gerami D. , Keenan, Jeremy David , Hamrah, Pedram , Lee, Hyunjoo, Barbato, John D, Weikert, Mitchell P. , Hood, Christopher, Woodward, Maria A. , Sugar, Alan, Shtein, Roni Mintz , Prescott, Christina R. , Haberman, Ilyse D. , Schrack, Katie E, Ritterband, David C. , Harris, David J, Ahmad, Sumayya , Srikumaran, Divya S. , Akpek, Esen K. , Tu, Elmer Yuchen , Miller, Donald M, Bernal, Maria, Shieh, Christine , Thorne, George, Sivaraman, Kavitha, Lin, Amy , Repine, Karen, Asbell, Penny A. , Ashe, S, Wallace, Michael, Iovieno, Alfonso , Teichman, Joshua C. , Robert, Marie-Claude , Harissi‐Dagher, Mona , Baxter, Stephanie A. , Benson, Matthew, Tone, Stephan Ong , Hassonlou, Mojgan, Yung, C.–W., Svanda, Kerri, Keppol, Stacy, Vyas, Neil M, McHam, Lisa, Veena, Mathew, Goshe, Jeffrey M. , Miller, Darby D. , Ma, Jeffrey H

Mayo Clinic

JAMA Ophthalmology | March 6, 2025 | Volume: 143 | Issue: 4 | Pages: 277

10.1001/jamaophthalmol.2024.6113 | PMID 40048191 Get It

Importance Evidence regarding suppressive valacyclovir treatment on postherpetic neuralgia is necessary to guide care. Objective To test the hypothesis that suppressive treatment with 1000 mg/d of oral valacyclovir for 12 months reduces the prevalence, severity, and duration of postherpetic neuralgia compared with placebo at 12 and 18 months in participants with herpes zoster ophthalmicus (HZO). Design, Setting, and Participants Multicenter, placebo-controlled randomized clinical trial including 527 immunocompetent, nonpregnant adults with history of HZO rash, documented keratitis, or iritis within 1 year and an estimated glomerular filtration rate of 45 mL/min/1.73 m 2 or greater. The study was conducted at 95 participating sites (in Canada, New Zealand, and the US) from November 2017 to June 2024 and participant visits occurred every 3 months. Intervention Treatment with 1000 mg/d of valacyclovir or placebo for 12 months. Main Outcomes and Measures Prevalence of postherpetic neuralgia, severity as determined by pain score (a score of ≥3 on a scale of 1-10), pain duration (≥3 months after HZO onset), and total daily dose of pain medication. Results Of the 527 participants (490 completed 12 months of treatment and 460 completed 18 months), 73 (14%) had postherpetic neuralgia and were analyzed by age at HZO onset (<60 years or ≥60 years) and disease duration (recent [<6 months] or chronic [≥6 months]). Of the 73 participants with postherpetic neuralgia (34 in the valacyclovir group and 39 in the placebo group), the mean age was 62.4 years (SD, 13.6 years), 59% were female, 5% were Black or African American, and 10% were Hispanic. The prevalence of postherpetic neuralgia at 12 months was not reduced by valacyclovir (12/32 [38%]) compared with placebo (14/35 [40%]) (between-group difference, 2.5% [95% CI, −20.8% to 25.8%]; P >.99). The participants who were younger than 60 years at HZO onset and had a chronic disease duration had lower pain scores in the valacyclovir group (mean score, 0.3 [SD, 0.9]) vs the placebo group (mean score, 0.8 [SD, 1.9]) at 12 months ( P = .045) and at 18 months (mean score, 0.2 [SD, 0.9] vs 1.0 [SD, 2.3], respectively; P = .02). There was a decrease in pain duration in the valacyclovir group at 18 months (mean, 13.6 [SD, 11.4] months) vs the placebo group (mean, 18.7 [SD, 29.5] months) (linear mixed-effects model between-group difference, −3.39 months [95% CI, −6.73 to −0.04 months]; P = .046). The total daily dose of neuropathic pain medication was lower in the valacyclovir group (mean, 271.4 [SD, 593.8] mg/d) vs the placebo group (mean, 363.4 [SD, 592.2] mg/d) at 12 months (linear mixed-effects model P = .006) and at 18 months (mean, 209.0 [SD, 412.8] mg/d vs 286.2 [SD, 577.9] mg/d, respectively; linear mixed-effects model P = .01). Conclusions and Relevance One year of suppressive treatment with valacyclovir was associated with a lower dosage of neuropathic pain medication. Participants in the valacyclovir group, who were younger at HZO onset and had a chronic disease duration, had lower pain scores. These secondary outcomes support consideration of 1 year of suppressive treatment with valacyclovir to reduce dosage of pain medications and pain due to HZO. Trial Registration ClinicalTrials.gov Identifier: NCT03134196
Spatially Resolved, Multiregion Proteomics for Prediction of Immunotherapy Outcome in Deficient Mismatch Repair Metastatic Colorectal Cancer
Saberzadeh-Ardestani, Bahar , Liu, Zhenglong , Stein, Mariam I. , Sherman, Will A., Trussoni, Christy E. , Abbott, Charles W. , Yan, Dongyao , Smith, Skyler , Shanmugam, Kandavel , Graham, Rondell P. , Levy, Joshua , Ördög, Tamás , Sherman, William , Sherman, Will A , Diallo, Alos , Levy, Joshua J , Ordog, Tamas , Sinicrope, Frank A , Graham, Rondell P , Smith, Skyler , Sinicrope, Frank A.

Mayo Clinic

Clinical Cancer Research | February 19, 2025 | Volume: 31 | Issue: 9 | Pages: 1783-1795

10.1158/1078-0432.ccr-24-0853 | PMID 39969975 Get It

Abstract Purpose: Digital proteomic profiling was performed to identify spatial context in relationship to patient response and survival after anti–PD-1 therapy in metastatic colorectal cancer. Experimental Design: Primary colorectal cancers with deficient mismatch repair from patients treated with anti–PD-1 antibodies were analyzed (N = 30) using digital spatial profiling (GeoMx nCounter). At the invasive margin, 71 proteins were profiled in 10 regions of interest/slide that were segmented into 3 compartments labeled with pan-cytokeratin (epithelia), CD45 (stromal cells), and SYTO13 (nuclei). In an independent cohort (n = 13), digital spatial profiling data and single-cell transcriptomic data were analyzed. Differential protein abundance, after Benjamini–Hochberg correction, was examined by clinical response and progression-free survival (PFS) using multivariable Cox regression. Results: Protein abundance varied significantly between epithelial and stromal compartments. Nonresponders to anti–PD-1 showed higher fibronectin and smooth muscle actin abundance in the epithelial compartment that was associated with significantly shorter PFS (adjusted HR: 6.49 and 4.52, respectively; P < 0.05). In CD45+ stroma, increased expression of proteins related to T cells (CD3 and CD4), NK cells (CD56), antigen presentation (CD40), immune activation (CD27, ICOS), and apoptosis (GZMA) were found in responders (vs nonresponders) to anti–PD-1; each marker was significantly associated with longer patient PFS (0.02 < adjusted HR < 0.17; P < 0.05). In a separate cohort, consistent results by compartment were found for fibronectin and CD56. Gene expression data revealed that fibronectin and smooth muscle actin were primarily derived from cancer-associated fibroblasts. Conclusions: Spatially resolved protein profiles within microenvironments of deficient mismatch repair colorectal cancers can influence patient response and survival after anti–PD-1, highlighting their potential clinical significance.
Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) and Metabolic Dysfunction‐Associated Steatohepatitis ( MASH
Younossi, Zobair M. , Sherman, Michael S., Anstee, Quentin M. , Cusi, Kenneth , Lazarus, Jeffrey V. , Schuppan, Detlef, Schattenberg, Jörn M. , Vos, Miriam B. , Anstee, Quentin M , Cusi, Kenneth , Lazarus, Jeffrey V , Schuppan, Detlef , Romero-Gómez, Manuel , Wong, Vincent Wai-Sun , Sanyal, A J , Loomba, Rohit , Schattenberg, Jörn M , Razavi, Homie , Sherman, Michael, Allen, Alina M. , Friedman, Scott L. , Lawitz, Eric , Wong, Vincent Wai‐Sun , Ratziu, Vlad , Hompesch, Marcus , Sanyal, Arun J. , Loomba, Rohit

Mayo Clinic

Alimentary Pharmacology & Therapeutics | February 19, 2025 | Volume: 61 | Issue: 9 | Pages: 1467-1478

10.1111/apt.70020 | PMID 39967239 Get It

ABSTRACT Background The continuum of metabolic syndrome encompasses a spectrum of dysfunctions impacting obesity‐linked insulin resistance, glucose homeostasis, lipid metabolism and pro‐inflammatory immune responses. The global prevalence of metabolic diseases, including diabetes, chronic liver disease, cardiometabolic disease and kidney disease, has surged in recent decades, contributing significantly to population mortality. Metabolic dysfunction‐associated steatotic liver disease (MASLD), formerly known as non‐alcoholic fatty liver disease, is a leading cause of liver disease worldwide. MASLD poses a significant global health challenge with its rising prevalence, placing a substantial burden on healthcare systems, impacts patient well‐being and incurs significant economic costs. Addressing MASLD requires a comprehensive understanding of its interconnected factors, including its prevalence, healthcare burden and economic implications. Lack of awareness, imprecise non‐invasive diagnostic methods and ineffective preventive interventions are core components of the MASLD‐related problem. Aim The aim of this article was to summarise the global burden of MASLD from the payer's perspective. Methods We carried out a review of the global comprehensive burden of MASLD. These topics led to discussions and insights by an expert panel during the 7th Metabolic Continuum Roundtable meeting, which took place in November 2023. This meeting focused on the burden, patient‐reported outcomes and health economics, from payor and societal perspectives, and aimed to identify opportunities for improving patient care, optimise resource allocation and mitigate the overall impact on individuals and society related to MASLD. During the roundtable, an emphasis emerged on the need for greater awareness and strategic deployment of diagnostic, therapeutic and preventative measures to address MASLD effectively. Conclusion The global burden of MASLD is high and growing. Prioritising the prevention of metabolic dysregulation and timely therapeutic interventions can yield a holistic strategy to combat MASLD, its progression and potentially lower disease costs. Trial Registration: NCT06309992
Increased Interaction between B Cells and CD3+ T Cells in Nonprogressors with Human Papillomavirus–Associated Oropharyngeal Squamous Cell Carcinoma
Bartemes, Kathleen R. , Moore, Raymond M. , Novotny, Brenna C. , Pavelko, Kevin D. , Sherman, William H., Rivera, Michael , García, Joaquín J. , Daniel, J. , Moore, Eric J. , Abel, Kathryn M. Van , Sherman, William , Sherman, Will A , Yin, Linda X , Ma, Daniel , Moore, Eric J , Van Abel, Kathryn M , Routman, David M , Pavelko, Kevin D , Novotny, Brenna , Yin, Linda X. , Routman, David M.

Mayo Clinic

Clinical Cancer Research | February 18, 2025 | Volume: 31 | Issue: 9 | Pages: 1719-1729

10.1158/1078-0432.ccr-24-2425 | PMID 39964349 Get It

Abstract Purpose: Tumor-infiltrating lymphocytes are associated with a decreased risk of recurrence in human papillomavirus–associated oropharyngeal squamous cell carcinoma. The composition and spatial distribution of tumor-infiltrating lymphocytes and tumor-infiltrating immune cells are not well characterized. Experimental Design: Formalin-fixed, paraffin-embedded primary and lymph node (LN) tumor tissues from 10 progressors (cases) and 10 matched nonprogressors (controls) were interrogated by imaging mass cytometry. Immune, stromal, and tumor cells were quantified from selected regions of interest using machine learning. Nearest neighbors, cell–cell interactions, and niche analyses were performed. Results: In primary regions of interest, immune cell, lymphocyte, T cell, CD8+ T cell, and innate cell prevalence was significantly greater in controls. High prevalence of immune cells, lymphocytes, innate cells, and CD4+ T cells in primary tissues was significantly associated with increased time to event (TTE). Although primary and LN prevalence of T cells, CD4+ T cells, CD8+ T cells, macrophages, and tumor cells were significantly correlated, differences in LNs were neither significant nor associated with TTE. Average distances between T cells and the nearest B cells and between lymphocytes and the nearest tumor cells were decreased in control primary tissues. Interactions between B and T cells were less organized in primary tissues from cases. A niche predominantly comprising lymphocytes was associated with longer TTE. Conclusions: In human papillomavirus–associated oropharyngeal squamous cell carcinoma, immune cell subset prevalence in primary tumors differs with outcome and is associated with TTE. Interactions between B cells and both T-cell subsets are associated with longer TTE, underscoring the importance of active intratumoral immune responses in outcomes.
Verdiperstat in Amyotrophic Lateral Sclerosis
Hayden, Douglas * deceased, Lai, Po-Ying, Donahue, Rachel, Chen, Hao-Wun, Nm, Mathai, Lopes, Gabriela, McCaffrey, Alexandra, Scalia, Jennifer , Luppino, Sarah , Lagier‐Tourenne, Clotilde , Sadri‐Vakili, Ghazaleh , Heintzman, Sarah, Sufit, Robert , Szymanski, April, Jenkins, Liberty, Martín, Alan, Greene, Ericka , Liao, Bing , Whitaker, Charles H. , Clawson, Lora , Uchil, Alpa, Riley, Kristen M., Arneklev, JinAe, Grogan, James , Su, Xiaowei , Mamarabadi, Mansoureh , Malcolm, Amber, Bazan, Tracy, Rad, Nassim, Wang, Leo H. , Piccione, Ezequiel, Thaisetthawatkul, Pariwat , Farmakidis, Constantine , Jabari, Duaa, Pasnoor, Mamatha , Brown, Robert H. , Houmani, Hajar, Douthwright, Catherine, Daniello, Kate, Suresh, Niraja, Farias, Jerrica, Chen, I-Hweii A. , Steijlen, Kara , Bhavaraju‐Sanka, Ratna, Jacobsen, Bill , Milliard, Jourdan, Bowser, Robert , Deboo, Anahita, Cartwright, Michael S. , Nance, Christopher , Yasek, Julia , Harms, Matthew B. , Burford, Matthew, Shrilla, David, Jones, Sarah , Solórzano, Guillermo, Li, Xiaoyan , Mahuwala, Zabeen , Kumaraswamy, Vishakhadatta Mathur, Baer, Michael , Bhuvaneswaran, Karthikeyan, Kaur, Jasdeep , Walk, David , Maiser, Sam , Mundwiler, Andrew, Meyer, Jenny A. , Soliven, Betty , Roos, Raymond, Mozaffar, Tahseen , Korb, Manisha Kak , Mullen, Jeffrey, Stommel, Elijah W. , Carberry, Nathan , Govindarajan, Raghav , Fournier, C. , Darki, Leila, Rodriguez, Rodrigo , McNeely, Whitney, Diaz‐Abad, Montserrat , Jin, Peter H., Chauhan, Chandana, Bobenhouse, James, Hayat, Ghazala , Bailey, Abbey, Bailey, Jesse, Barlow, Victoria , Bulat, Allison, Changkuon, Genevive, Cirino, Melissa, Deignan, Cristina, Deirmendjian, Emma, Mattos, Annette De, DiStefano, Sofia, Drake, Kristin, Estes, Michaela, Faulconer, Kenneth, Figueroa-Szostek, Precious, Garozzo, Tessa, Hasenoehrl, Meredith Gibbons, Henrique, Jennifer, Henrique, Natalie, Hurwitz, Samuel , Igne, Courtney, Irwin, Liam, Jentoft, Katie, Jordan, Boglarka, Katsovskiy, Igor, Kharakozova, Olga, Kolvek, Taylor, Korin, Alexander, La, Thuong, Li, Haining , Nguyen, Joey, Novak, Ilya, Ortiz, Ricardo, Ostrow, Joe, Pagliaro, Jaclyn , Palillo, Jack, Patterson, J.C., Phan, Minh , Popel, Najla , Proueng, Serena, Rosenthal, Jesse, Small, Catherine B. , Tarasenko, Natalia, Thomas, M., Vigneswaran, Prasha, Wahab, Yusra, Whitworth, Isaac, Wright, Spencer, Santiago, Diana De, Félix, Adrián, Garrett, Karly, Hamilton, Jenny, Khan, Kamran, Lovett, Marlee, Nelson, Linda S., Pabon, Marissa, Rede, Diana, Bolger, Patrick, Fetouh, Ahmed , Woodcook, Joan, Kamp, Cornelia , Kennedy, Julie, McGarry, Andrew , Torti, Margherita , Andrews, Jinsy , Quintana, Melanie , Saville, Benjamin R. , Detry, Michelle A. , Vestrucci, Matteo, Marion, Joseph , Young, Eufrosina , Chase, Marianne, Pothier, Lindsay , Harkey, Brittney, Yu, Hong , Sherman, Alex, Hall, Meghan, Kittle, Gale, Connolly, Mariah, D’Agostino, Derek, Tustison, Eric, Scirocco, Erica, Alameda, Gustavo, Locatelli, Eduardo, Ho, Doreen , Quick, Adam , Heitzman, Daragh, Ajroud‐Driss, Senda , Appel, Stanley H. , Shroff, Sheetal , Katz, Jonathan, Felice, Kevin J. , Maragakis, Nicholas J., Simmons, Zachary , Olney, Nicholas , Miller, Timothy M. , Fernandes, Joseph Americo, Ilieva, Hristelina , Jawdat, Omar, Weiss, Michael D. , Foster, Laura A. , Owegi, Margaret, Newman, Daniel S. , Arcila-Londono, Ximena , Jackson, Carlayne E. , Heiman‐Patterson, Terry , Fee, Dominic , Lewis, Richard A. , Rosenfeld, Jeffrey , Johnson, Kristin, Elliott, Matthew, Kasarskis, Edward J. , Rutkove, Seward B. , McIlduff, Courtney, Bedlack, Richard , Elman, Lauren , Goyal, Namita , Rezania, Kourosh , Twydell, Paul, Benatar, Michael , Glass, Jonathan D. , Jones, Vovanti , Zilliox, Lindsay , Wymer, James , Beydoun, Said R., Shah, Jaimin , Pattee, Gary L. , Martinez‐Thompson, Jennifer M. , Nayar, Shakti, Donohue, Mary V., Grossman, Katheryn, Campbell, Daniel , Qureshi, Irfan , Babu, Suma , Group, HEALEY ALS Platform Trial Study, Maragakis, Nicholas J. , Scirocco, Erica , Martinez-Thompson, Jennifer, Scirocco, Erica , Simmons, Zachary , Maragakis, Nicholas , Bedlack, Richard S , Walk, David , Hayden, Douglas, Wang, Jianing , Mathai, N. M., Kolb, Stephen J. , Szymanski, April L., Liao, Bing, Arneklev, JinAe, Malcolm, Amber, Feldman, Eva L. , Statland, Jeffrey , Dimachkie, Mazen M. , Ghasemi, Mehdi , Houmani, Hajar, Pasinelli, Piera , Milliard, Jourdan, Gutmann, Ludwig , Diaz, Frank , Shrilla, David, Rakočević, Goran , Quinn, Colin , Borg, David, Bhuvaneswaran, Karthikeyan, Robbins, Nathaniel M. , Oskarsson, Björn , Chuquilin, Miguel , McNeely, Whitney, Bobenhouse, James, Staff, Nathan P. , Arroyave, Luisa, Bulat, Allison , Changkuon, Genevive, Cirino, Melissa, Deignan, Cristina, Deirmendjian, Emma, Estes, Michaela, Figueroa-Szostek, Precious, Garozzo, Tessa, Henrique, Jennifer, Henrique, Natalie, Hurwitz, Samuel, Irwin, Liam, Jordan, Boglarka, Kolvek, Taylor, Korin, Alexander, Nguyen, Joey, Novak, Ilya, Ostrow, Joe, Palillo, Jack, Patel, Payal, Patterson, Janae, Phan, Minh, Proueng, Serena, Rosenthal, Jesse, Small, Catherine, Thomas, Mirna, Felix, Adrian, Khan, Kamran, Lovett, Marlee, Nelson, Linda, Rede, Diana, Bolger, Patrick, Fetouh, Ahmed, Woodcook, Joan, Kennedy, Julie, Paganoni, Sabrina , Macklin, Eric A. , Chibnik, Lori Beth , McGlothlin, Anna , Shefner, Jeremy M. , Berry, James D. , Giacomelli, Elisa , Goutman, Stephen A. , Fernandes, J. Americo, Vu, Tuan , Ladha, Shafeeq , Newman, Daniel S., Swenson, Andrea , Caress, James B. , Peltier, Amanda , Johnson, Kristin, Cohen, Jeffrey Allen , Granit, Volkan , Donohue, Mary, Cudkowicz, Merit , Group, HEALEY ALS Platform Trial Study

Mayo Clinic

JAMA Neurology | February 17, 2025 | Volume: 82 | Issue: 4 | Pages: 333

10.1001/jamaneurol.2024.5249 | PMID 40067754 Get It

ImportanceMyeloperoxidase is one of the most abundant peroxidase enzymes in activated myeloid cells. Myeloperoxidase inhibitors may have a clinical benefit in amyotrophic lateral sclerosis (ALS) by slowing neurodegeneration via reduced neuroinflammation and oxidative stress.ObjectiveTo determine the safety, tolerability, and efficacy of verdiperstat, a selective myeloperoxidase inhibitor, in ALS.Design, Settings, and ParticipantsVerdiperstat was tested as a regimen of the HEALEY ALS Platform Trial, a multicenter, double-blind, perpetual platform design, randomized clinical trial, with sharing of trial infrastructure and placebo data across multiple regimens. The study was conducted at 54 ALS referral centers across the US from July 2020 to April 2022. Adult participants with a diagnosis of clinically possible, probable, laboratory-supported probable, or definite ALS defined by the revised El Escorial criteria were randomized to verdiperstat or regimen-specific placebo. An additional group of participants concurrently randomized to placebo from other regimens was included in the analyses.InterventionsEligible participants were randomized in a 3:1 ratio to receive oral verdiperstat, 600 mg, twice daily or matching placebo for a planned placebo-controlled duration of 24 weeks.Main Outcomes and MeasuresThe primary efficacy outcome was change from baseline through week 24 in disease severity, as measured by a joint model of ALS Functional Rating Scale–Revised and survival, with the treatment effect quantified by the disease rate ratio (DRR), with DRR less than 1 indicating a slowing in disease progression of verdiperstat relative to placebo.ResultsA total of 167 participants (mean [SD] age, 58.5 [11.4] years; 59 [35.3%] female; 108 [64.6%] male) were randomized to either verdiperstat (126 [75.4%]) or to placebo (41 [25.6%]). Among the participants randomized to the verdiperstat regimen, 130 (78%) completed the trial. The estimated DRR was 0.98 (95% credible interval, 0.77-1.24; posterior probability = 0.57 for slowing of disease progression [DRR <1]). Verdiperstat was estimated to slow progression by 2% vs placebo (95% credible interval, −23% to 24%; posterior probability 0.57). Verdiperstat was overall safe and well tolerated. Common adverse events in the verdiperstat group were nausea, insomnia, and elevated thyrotropin levels.Conclusions and RelevanceResults demonstrate that treatment with verdiperstat was unlikely to alter disease progression in ALS.Trial RegistrationClinical Trial Identifiers: NCT04297683 and NCT04436510
Pridopidine in Amyotrophic Lateral Sclerosis
Hayden, Douglas, Lai, Po-Ying, Donahue, Rachel, Chen, H.Y., Mathai, Nithya, Lopes, Gabriela, McCaffrey, Alexandra, Scalia, Jennifer , Luppino, Sarah , Lagier‐Tourenne, Clotilde , Sadri‐Vakili, Ghazaleh , Heintzman, Sarah, Sufit, Robert , Szymanski, April, Jenkins, Liberty, Martin, A. D. , Greene, Ericka , Thonhoff, Jason R., Liao, Bing , Whitaker, Charles H. , Clawson, Lora , Uchil, Alpa, Riley, Kristen M., Arneklev, JinAe, Grogan, James , Su, Xiaowei , Mamarabadi, Mansoureh , Malcolm, Amber, Bazan, Tracy, Rad, Nassim, Wang, Leo H. , Piccione, Ezequiel, Thaisetthawatkul, Pariwat , Farmakidis, Constantine , Jabari, Duaa, Pasnoor, Mamatha , Brown, Robert H. , Ghasemi, Mehdi, Houmani, Hajar, Douthwright, Catherine, Daniello, Kate, Suresh, Niraja, Farias, Jerrica, Chen, I-Hweii A. , Steijlen, Kara , Bhavaraju‐Sanka, Ratna, Jacobsen, Bill , Milliard, Jourdan, Bowser, Robert , Deboo, Anahita, Cartwright, Michael S. , Nance, Christopher , Yasek, Julia , Harms, Matthew , Burford, Matthew, Shrilla, David, Jones, Sarah , Solórzano, Guillermo, Li, Xiaoyan , Mahuwala, Zabeen , Kumaraswamy, Vishakhadatta Mathur, Baer, Michael , Bhuvaneswaran, Karthikeyan, Maiser, Sam , Mundwiler, Andrew, Meyer, Jenny, Soliven, Betty , Roos, Raymond P. , Habib, Ali A. , Mozaffar, Tahseen , Korb, Manisha Kak , Mullen, Jeffrey, Stommel, Elijah W. , Carberry, Nathan , Govindarajan, Raghav , Glass, Jonathan D. , Fournier, Christina , Darki, Leila, Rodriguez, Rodrigo , McNeely, Whitney, Diaz‐Abad, Montserrat , Jin, Peter H., Chauhan, Chandana, Bobenhouse, James, Hayat, Ghazala , Bailey, Abbey, Bailey, Jesse, Barlow, Victoria , Bulat, Allison, Changkuon, Genevive, Cirino, Melissa, Deignan, Cristina, Deirmendjian, Emma, Mattos, Annette De, DiStefano, Sofia, Drake, Kristin, Estes, Michaela, Faulconer, Kenneth, Figueroa-Szostek, Precious, Garozzo, Tessa, Hasenoehrl, Meredith Gibbons, Henrique, Jennifer, Henrique, Natalie, Hurwitz, Samuel , Igne, Courtney, Irwin, L. R., Jentoft, Katie, Jordan, Boglarka, Katsovskiy, Igor, Kharakozova, Olga, Kolvek, Taylor, Korin, Alexander, La, Thuong, Li, Haining , Nguyen, Joey, Novak, Ilya, Ortiz, Ricardo, Ostrow, Joe, Pagliaro, Jaclyn , Palillo, Jack, Patel, Payal , Patterson, Janae, Phan, Minh , Popel, Najla , Proueng, Serena, Rosenthal, Jesse, Small, Catherine B. , Tarasenko, Natalia, Thomas, Mirna, Vigneswaran, Prasha, Wahab, Yusra, Whitworth, Isaac, Wright, Spencer, Connolly, Mariah, Santiago, Diana De, Felix, A. John William , Garrett, Karly, Hamilton, Jenny, Khan, Kamran , Lovett, Marlee, Nelson, Linda S., Pabon, Marissa, Rede, Diana, Bolger, Patrick, Fetouh, Ahmed , Woodcook, Joan, Kamp, Cornelia , Kennedy, Julie, McGarry, Andrew , Torti, Margherita , Quintana, Melanie , Saville, Benjamin R. , Detry, Michelle A. , Vestrucci, Matteo, Marion, Joe , Heiman‐Patterson, Terry , Chase, Marianne, Pothier, Lindsay , Harkey, Brittney, Yu, Hong , Sherman, Alexander , Hall, Meghan, Kittle, Gale, Andrews, Jinsy , D’Agostino, Derek, Tustison, Eric, Scirocco, Erica , Alameda, Gustavo, Locatelli, Eduardo, Ho, Doreen , Quick, Adam , Ajroud‐Driss, Senda , Katz, Jonathan, Heitzman, Daragh, Appel, Stanley H. , Shroff, Sheetal , Felice, Kevin J. , Maragakis, Nicholas J., Simmons, Zachary , Olney, Nicholas , Weiss, Michael D. , Fernandes, Joseph Americo, Jawdat, Omar, Owegi, Margaret, Foster, Laura A. , Ilieva, Hristelina , Newman, Daniel S. , Arcila-Londono, Ximena , Jackson, Carlayne E. , Lewis, Richard A. , Fee, Dominic , Elliott, Matthew, Bedlack, Richard , Kasarskis, Edward J. , Elman, Lauren , Rosenfeld, Jeffrey , Walk, David , McIlduff, Courtney, Twydell, Paul, Young, Eufrosina , Johnson, Kristin, Rezania, Kourosh , Goyal, Namita , Benatar, Michael , Jones, Vovanti , Shah, Jaimin , Beydoun, Said R., Wymer, James , Zilliox, Lindsay , Nayar, Shakti, Pattee, Gary L. , Martinez‐Thompson, Jennifer M. , Leitner, Melanie , Chen, Kelly , Goldberg, Y. Paul, Cohen, Yaël C. , Geva, Michal , Hayden, Michael R. , Group, HEALEY ALS Platform Trial Study, Scirocco, Erica , Martinez-Thompson, Jennifer, Simmons, Zachary , Bedlack, Richard S , Walk, David , Wang, Jianing , Mathai, N. M., Kolb, Stephen J. , Szymanski, April L., Martin, Alan, Liao, Bing, Arneklev, JinAe, Malcolm, Amber, Feldman, Eva L. , Statland, Jeffrey , Dimachkie, Mazen M. , Ghasemi, Mehdi , Houmani, Hajar, Pasinelli, Piera , Milliard, Jourdan, Gutmann, Ludwig , Harms, Matthew B. , Diaz, Frank , Shrilla, David, Rakočević, Goran , Quinn, Colin , Borg, David, Bhuvaneswaran, Karthikeyan, Kaur, Jasdeep, Rutkove, Seward B. , Rao, Pooja, Robbins, Nathaniel M. , Granit, Volkan , Chuquilin, Miguel , McNeely, Whitney, Bobenhouse, James, Staff, Nathan P. , Arroyave, Luisa, Bulat, Allison , Changkuon, Genevive, Cirino, Melissa, Deignan, Cristina, Deirmendjian, Emma, Figueroa-Szostek, Precious, Garozzo, Tessa, Henrique, Jennifer, Henrique, Natalie, Hurwitz, Samuel, Irwin, Liam, Kolvek, Taylor, Korin, Alexander, Ostrow, Joe, Palillo, Jack, Phan, Minh, Proueng, Serena, Rosenthal, Jesse, Small, Catherine, Thomas, Mirna, Garrett, Karly, Nelson, Linda, Rede, Diana, Bolger, Patrick, Fetouh, Ahmed, Woodcook, Joan, Kennedy, Julie, Shefner, Jeremy M. , Oskarsson, Björn , Macklin, Eric A. , Chibnik, Lori Beth , McGlothlin, Anna , Berry, James D. , Babu, Suma , Giacomelli, Elisa , Maragakis, Nicholas J. , Mill, Jonathan , Goutman, Stephen A. , Fernandes, J. Americo, Vu, Tuan , Newman, Daniel S., Ladha, Shafeeq , Caress, James B. , Swenson, Andrea , Peltier, Amanda , Johnson, Kristin, Cohen, Jeffrey Allen , Goldberg, Y. Paul, Paganoni, Sabrina , Cudkowicz, Merit

Mayo Clinic

JAMA | February 17, 2025 | Volume: 333 | Issue: 13 | Pages: 1128

10.1001/jama.2024.26429 | PMID 40067755 Get It

ImportanceAmyotrophic lateral sclerosis (ALS) is a fatal disease. The sigma-1 (σ1) receptor emerged as a target for intervention.ObjectiveTo determine the effects of pridopidine, a σ1-receptor agonist, in ALS.Design, Settings, and ParticipantsPridopidine was tested as a regimen of the HEALEY ALS Platform Trial, a phase 2/3, multicenter, randomized, double-blind, platform trial. The study was conducted at 54 sites in the US from January 2021 to July 2022 (final follow-up, July 14, 2022). A total of 163 participants with ALS were randomized to receive pridopidine or placebo. An additional 122 concurrently randomized participants were assigned to receive placebo in other regimens and included in the analyses.InterventionsEligible participants were randomized 3:1 to receive oral pridopidine 45 mg twice daily (n = 121) or matching oral placebo (n = 42) for a planned duration of 24 weeks.Main Outcomes and MeasuresThe primary efficacy outcome was change from baseline through week 24 in ALS disease severity, analyzed using a bayesian shared parameter model, which has components for function (Revised Amyotrophic Lateral Sclerosis Functional Rating Scale [ALSFRS-R]) and survival that were linked through an integrated estimate of treatment-dependent disease slowing across these 2 components. This was denoted as the disease rate ratio (DRR), with DRR less than 1 indicating a slowing in disease progression on pridopidine relative to placebo. There were 5 key secondary end points: time to 2-point or greater reduction in ALSFRS-R total score among participants with bulbar dysfunction at baseline, rate of decline in slow vital capacity among participants with bulbar dysfunction at baseline, percentage of participants with no worsening in the ALSFRS-R bulbar domain score, time to 1-point or greater change in the ALSFRS-R bulbar domain score, and time to death or permanent assisted ventilation.ResultsAmong 162 patients (mean age, 57.5 years; 35% female) who were randomized to receive the pridopidine regimen and included in the primary efficacy analysis, 136 (84%) completed the trial. In the primary analysis comparing pridopidine vs the combined placebo groups, there was no significant difference between pridopidine and placebo in the primary end point (DRR, 0.99 [95% credible interval, 0.80-1.21]; probability of DRR <1, 0.55) and no differences were seen in the components of ALSFRS-R or survival. There was no benefit of pridopidine on the secondary end points. In the safety dataset (pridopidine, n = 121; placebo, n = 163), the most common adverse events were falls (28.1% vs 29.3%, respectively) and muscular weakness (24.0% vs 31.7%, respectively).Conclusions and RelevanceIn this 24-week study, pridopidine did not impact the progression of ALS.Trial RegistrationClinicalTrials.gov Identifiers: NCT04297683, NCT04615923